Denosumab Market Forecast Reveals Where Future Industry Value Will Be Created
Through market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports provide more actionable and strategically valuable research.
Denosumab Market Forecast Highlighting Growth From $4.05 Billion To $6.05 Billion
The denosumab market has undergone significant expansion over recent years. Its valuation is projected to increase from $3.67 billion in 2025 to $4.06 billion in 2026, reflecting a compound annual growth rate (CAGR) of 10.7%. This historical growth has been driven by several factors, including the high incidence of osteoporosis and other bone-related conditions, a steadily aging population, early regulatory approvals for denosumab treatments, enhanced capacity in hospitals and specialty clinics, and growing patient awareness regarding fracture risks.
The denosumab market is projected to experience substantial growth over the coming years, reaching a value of $6.06 billion by 2030, driven by a compound annual growth rate (CAGR) of 10.5%. This anticipated expansion is fueled by several key factors, including progress in precision medicine and biologics, the broadening of homecare and ambulatory services, greater funding for bone health studies, the launch of advanced denosumab products, and escalating demand within emerging economies. Among the prominent trends influencing this period are the rising utilization of monoclonal antibodies, the widening scope of osteoporosis screening initiatives, customized therapeutic strategies for managing bone metastases, the expansion of at-home injection therapies, and heightened public consciousness regarding bone wellness among older populations.
Download A Free Sample Report For Comprehensive Market Insights:
Denosumab Market Expansion Drivers: What Is Shaping Future Growth?
The growing incidence of osteoporosis is anticipated to boost the denosumab market in the coming period. Osteoporosis is a health issue characterized by fragile bones, leading to reduced bone density and an elevated likelihood of fractures. Denosumab addresses this condition by inhibiting bone resorption through targeting the RANK ligand. For example, in September 2023, the National Center for Biotechnology Information, a US government agency, reported that data from the Canadian Longitudinal Study on Aging indicated a 12.7% prevalence of physician-diagnosed osteoporosis and a 5.9% rate of DXA-confirmed osteoporosis among community-dwelling older females. Moreover, a cross-sectional study by Buttros and colleagues found a 24.6% occurrence of osteoporosis in postmenopausal women aged 40 to 75, identified via bone mineral density (BMD) assessments. Consequently, the rising frequency of osteoporosis is fueling the expansion of the denosumab market.
The growth of the healthcare sector is set to drive the denosumab market forward in the future. The healthcare industry encompasses entities that provide medical care, create treatments, and deliver products and technologies aimed at preserving and enhancing human health. This sector is expanding due to an increased need for medical services, fueled by aging and growing global populations. Denosumab contributes to the healthcare field by offering an effective treatment for osteoporosis and cancer-related bone deterioration, thereby enhancing patient well-being. For instance, in May 2023, the American Health Care Association, a US-based nonprofit, reported that the number of hospitals in the US rose to 6,129 in 2023 from 6,093 in 2022. Thus, the enlargement of the healthcare industry is propelling the denosumab market’s advancement.
Denosumab Market Segment Analysis: What Are The Major Market Categories?
The denosumab market covered in this report is segmented –
1) By Drug Classification: Prolia, Xgeva
2) By Type: 60 mg, 120 mg
3) By End-Users: Hospitals, Homecare, Specialty Clinics, Ambulatory Surgical Centers
Subsegments:
1) By Prolia: Prolia 60 Mg Injection, Prolia 1-Year Dosing Schedule, Prolia Osteoporosis Treatment
2) By Xgeva: Xgeva 120 Mg Injection, Xgeva Monthly Dosing Schedule, Xgeva Bone Metastases Management
Denosumab Market Strategic Trends: What Is Defining The Next Phase Of Growth?
Key players in the denosumab market are intensifying their focus on broadening international clinical trials and securing faster regulatory approvals to enhance their market standing and improve patient access to treatment. Clinical trials involve studies conducted on humans to assess the safety and effectiveness of new drugs or therapies. For example, in May 2023, Boan Biotech, a biopharmaceutical firm headquartered in China, launched a global multicenter Phase 3 clinical trial for its denosumab biosimilars BA6101 (Boyoubei) and BA1102, with the first patient enrolled across Europe, the United States, and Japan. This initiative follows the company’s 2022 approval from the NMPA for Boyoubei, intended for postmenopausal women at elevated fracture risk. By pushing forward with global clinical development and building regulatory approval momentum, firms strengthen their competitiveness within the denosumab market.
Denosumab Market Leading Companies Driving Competitive Growth
Major companies operating in the denosumab market are Amgen Inc., Fresenius SE & Co KGaA, Amneal Pharmaceuticals Inc., Dr Reddy’s Laboratories Ltd, Biocon Ltd, Sandoz Group AG, Samsung Bioepis Co Ltd, Celltrion Inc, Organon & Co, Shanghai Henlius Biotech Inc, Teva Pharmaceutical Industries Ltd, Accord Healthcare Ltd, CuraTeQ Biologics Pvt Ltd, AryoGen Pharmed Co, BioXpress Therapeutics AG, Henlius Biotech Co Ltd, JHL Biotech Inc, Oncobiologics Inc, Teva International GmbH (Teva biosimilars unit), Hikma Pharmaceuticals PLC, Gedeon Richter Plc, Accord BioPharma Inc
Access The Complete Denosumab Market Report:
Denosumab Market Largest Region: Which Geography Holds The Highest Market Share?
North America was the largest region in the denosumab market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the denosumab market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
